HIV drug to be more affordable in SA

22 September 2017 - 07:33 By Tamar Kahn
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now
The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment.
The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment.
Image: Gallo Images/iStockphoto

A state-of-the art HIV pill containing Dolutegravir‚ already widely used in rich countries‚ is set to become more quickly available at an affordable price in SA‚ thanks to an agreement announced by UNAIDS in New York on Thursday night.

The deal guarantees a maximum price of $75 per person per year for three-in-one pills containing Dolutegravir‚ Tenofovir and Lamivudine‚ made by pharmaceutical companies Mylan and Aurobindo under licence from Viiv Healthcare.

The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment. It is also good news for patients‚ as recent research has shown Dolutegravir is more effective and better tolerated than antiretrovirals such as Efavirenz and Nevirapine.

Business Day 

subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now